A look into BioAtla Inc (BCAB)’s deeper side

With 1.68 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.02 million shares. The 52-week range on BCAB shows that it touched its highest point at $4.02 and its lowest point at $0.38 during that stretch. It currently has a 1-year price target of $8.67. Beta for the stock currently stands at 1.15.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BCAB was down-trending over the past week, with a drop of -27.41%, but this was down by -31.93% over a month. Three-month performance dropped to -77.02% while six-month performance fell -81.11%. The stock lost -85.59% in the past year, while it has lost -42.47% so far this year. A look at the trailing 12-month EPS for BCAB yields -1.70 with Next year EPS estimates of -1.41. For the next quarter, that number is -0.39. This implies an EPS growth rate of 40.93% for this year and 7.54% for next year. EPS is expected to grow by 18.02% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -25.30%.

Float and Shares Shorts:

At present, 58.02 million BCAB shares are outstanding with a float of 49.70 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BCAB since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$1.525 being high and -$1.525 being low. For BCAB, this leads to a yearly average estimate of -$1.525. Based on analyst estimates, the high estimate for the next quarter is -$0.39 and the low estimate is -$0.39. The average estimate for the next quarter is thus -$0.39.